1-3 of 3
Marja Puurunen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Clinical Trials & Observations
Guy Young, Kaan Kavakli, Robert Klamroth, Tadashi Matsushita, Flora Peyvandi, Steven W. Pipe, M.D., Savita Rangarajan, Ming-Ching Shen, Alok Srivastava, Jing Sun, Huyen A Tran, Chur-Woo You, Bulent Bülent Zülfikar, Laurel A. Menapace, Chuanwu Zhang, Yuqian Shen, Marja Puurunen, Marek Demissie, Gili Kenet
Journal: Blood
Blood blood.2024027008.
https://doi.org/10.1182/blood.2024027008
Published: 2025
Includes: Supplemental data
Journal Articles

Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE

Steven W. Pipe, Kaan Kavakli, Tadashi Matsushita, Huyen Tran, Bulent Zulfikar, Laurel Menapace, Marja Puurunen, Wenruo Hu, Yuqian Shen, Chanchala Kaddi, Vanessa Salinas
Journal: Blood
Blood (2024) 144 (Supplement 1): 128.
https://doi.org/10.1182/blood-2024-206946
Published: 2024
Journal Articles

Fitusiran Population Pharmacokinetic and Pharmacodynamic Modeling Utilizing Phase 3 Clinical Trial Data to Confirm Doses Tested in Phase 3 Trials to Support an Antithrombin-Based Dose Regimen

Kumpal Madrasi, Pratik Bhagunde, Sajida Iqbal, Marja Puurunen, Marek Demissie, Shauna Andersson, Sreeraj Macha, Malidi Ahamadi
Journal: Blood
Blood (2023) 142 (Supplement 1): 2614.
https://doi.org/10.1182/blood-2023-189409
Published: 2023